Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines.
暂无分享,去创建一个
[1] C. Eccleston,et al. Systematic review and meta-analysis of psychological therapies for children with chronic pain. , 2014, Journal of pediatric psychology.
[2] P. Eckburg,et al. Day 4 Clinical Response of Ceftaroline Fosamil Versus Ceftriaxone for Community-Acquired Bacterial Pneumonia , 2012 .
[3] B. Limbago,et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] L. Mandell,et al. Methicillin-Resistant Staphylococcus aureus and Community-Acquired Pneumonia: An Evolving Relationship , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] D. Paterson,et al. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] M. Kollef,et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] D. Nassisi,et al. Evidence-based guidelines for evaluation and antimicrobial therapy for common emergency department infections. , 2012, Emergency medicine practice.
[8] Samuel M. Brown,et al. Hospital admission decision for patients with community-acquired pneumonia: variability among physicians in an emergency department. , 2012, Annals of emergency medicine.
[9] Jiaquan Xu,et al. Deaths: final data for 2008. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[10] B. Cao,et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. , 2011, International journal of antimicrobial agents.
[11] A. Akram,et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] B. Limbago,et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] S. Kaplan,et al. Staphylococcus aureus Pneumonia in Children in the Era of Community-acquired Methicillin-resistance at Texas Children's Hospital , 2011, The Pediatric infectious disease journal.
[14] Jianguo Tang,et al. Procalcitonin guidance for reduction of antibiotic use in low‐risk outpatients with community‐acquired pneumonia , 2011, Respirology.
[15] Ronald N. Jones,et al. LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States , 2011, Antimicrobial Agents and Chemotherapy.
[16] Samir N. Patel,et al. Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada , 2011, Antimicrobial Agents and Chemotherapy.
[17] C. Ginocchio. Strengths and Weaknesses of FDA-Approved/Cleared Diagnostic Devices for the Molecular Detection of Respiratory Pathogens , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] L. Peterson. Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Kristine M Hujer,et al. Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] J. Bartlett. Diagnostic tests for agents of community-acquired pneumonia. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Brad Spellberg,et al. Combating antimicrobial resistance: policy recommendations to save lives. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Peter Bacchetti,et al. Effect of emergency department crowding on pneumonia admission care components. , 2011, The American journal of managed care.
[23] H. D. Friedland,et al. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.
[24] C. Fischer,et al. Absolute lymphocyte count in the emergency department predicts a low CD4 count in admitted HIV-positive patients. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[25] Elizabeth A. Rechtsteiner,et al. Ambulatory medical care utilization estimates for 2007. , 2011, Vital and health statistics. Series 13, Data from the National Health Survey.
[26] J. Milanowski,et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.
[27] C. Schumann,et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.
[28] Y. Hsieh,et al. A meta-analysis of point-of-care laboratory tests in the diagnosis of novel 2009 swine-lineage pandemic influenza A (H1N1). , 2011, Diagnostic microbiology and infectious disease.
[29] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] K. Krause,et al. Evaluation of Pneumococci From the United States (USA) Pediatric Patients Isolated During the 2009 AWARE Program , 2011 .
[31] You-ning Liu,et al. Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease , 2010, Antimicrobial Agents and Chemotherapy.
[32] T. File,et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] P. Duca,et al. Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department , 2010, Emergency Medicine Journal.
[34] M. J. Hall,et al. National Hospital Discharge Survey: 2007 summary. , 2010, National health statistics reports.
[35] Y. Shemer-Avni,et al. Respiratory Viruses in Adults With Community-Acquired Pneumonia , 2010, Chest.
[36] M. Wilcox,et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] A. Akram,et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis , 2010, Thorax.
[38] Y. Loke,et al. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis , 2010, Thorax.
[39] R. Daum,et al. Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic , 2010, Clinical Microbiology Reviews.
[40] F. Martínez Sagasti,et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. , 2010, JAMA.
[41] G. Erdem,et al. Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii , 2010, Pediatric Radiology.
[42] T. File,et al. Burden of Community-Acquired Pneumonia in North American Adults , 2010, Postgraduate medicine.
[43] R. Lynfield,et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. , 2010, The Journal of infectious diseases.
[44] S. Kaplan,et al. Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children , 2010, Pediatrics.
[45] Dominic E Dwyer,et al. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. , 2009, The New England journal of medicine.
[46] C. Reed,et al. Staphylococcus aureus community-onset pneumonia in patients admitted to children's hospitals during autumn and winter of 2006–2007 , 2009, Epidemiology and Infection.
[47] Samuel M. Brown,et al. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia* , 2009, Critical care medicine.
[48] S. Weingart,et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. , 2009, Annals of emergency medicine.
[49] T. Bregenzer,et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.
[50] D. Vinh,et al. Linezolid: a review of safety and tolerability. , 2009, The Journal of infection.
[51] D. Levine,et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] D. Farrell,et al. Increase in Pneumococcus Macrolide Resistance, United States , 2009, Emerging infectious diseases.
[53] A. Hidrón,et al. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. , 2009, The Lancet. Infectious diseases.
[54] T. Welte,et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality , 2009, Thorax.
[55] Stefano Di Bartolomeo,et al. Evaluation of lung ultrasound for the diagnosis of pneumonia in the ED. , 2009, The American journal of emergency medicine.
[56] Philip M Polgreen,et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. , 2009, Annals of emergency medicine.
[57] M. Niederman,et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] S. Richter,et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] R. Balk. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia , 2009 .
[60] J. Maurer. Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia , 2009 .
[61] B. Thiers. Increased US Emergency Department Visits for Skin and Soft Tissue Infections, and Changes in Antibiotic Choices, During the Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus , 2009 .
[62] K. Shimada,et al. Antimicrobial susceptibility of pathogens isolated from more than 10 000 patients with infectious respiratory diseases: a 25-year longitudinal study , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[63] E. Rackow. Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.
[64] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[65] C. Tanaseanu,et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. , 2008, Diagnostic microbiology and infectious disease.
[66] G. Tillotson,et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. , 2008, The Journal of antimicrobial chemotherapy.
[67] David J. Ecker,et al. Ibis T5000: a universal biosensor approach for microbiology , 2008, Nature Reviews Microbiology.
[68] M. Kollef,et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] W. Schaffner,et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. , 2008, The Journal of infectious diseases.
[70] A. Anzueto,et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. , 2008, Chest.
[71] R. Paoloni,et al. Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia , 2008, Emergency Medicine Journal.
[72] D. Talan,et al. Diagnosis and Management of Pneumonia in the Emergency Department , 2008, Infectious Disease Clinics of North America.
[73] Roberta B Carey,et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. , 2007, JAMA.
[74] L. Friedrich,et al. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.
[75] P. Appelbaum. Microbiology of antibiotic resistance in Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[76] A. Pakyz,et al. The Utility of Hospital Antibiograms as Tools for Guiding Empiric Therapy and Tracking Resistance: Insights from the Society of Infectious Diseases Pharmacists , 2007, Pharmacotherapy.
[77] Susan S. Huang,et al. Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusetts Following Universal Immunization of Infants With Pneumococcal Conjugate Vaccine , 2007, The Pediatric infectious disease journal.
[78] D. Rasko,et al. Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005 , 2007, The Pediatric infectious disease journal.
[79] F. Tenover,et al. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[80] John Stelling,et al. Medical Microbiology: Analysis and Presentation of Cumulative Antibiograms: A New Consensus Guideline from the Clinical and Laboratory Standards Institute , 2007 .
[81] T. Marrie,et al. Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit: A Descriptive Study , 2007, Medicine.
[82] J. Bartlett,et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] M. Pichichero,et al. Increased Antimicrobial Resistance Among Nonvaccine Serotypes of Streptococcus pneumoniae in the Pediatric Population After the Introduction of 7-Valent Pneumococcal Vaccine in the United States , 2007, The Pediatric infectious disease journal.
[84] Ronald N. Jones,et al. Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program , 2007, Antimicrobial Agents and Chemotherapy.
[85] Roberta B Carey,et al. Methicillin-resistant S. aureus infections among patients in the emergency department. , 2006, The New England journal of medicine.
[86] C. Bridges,et al. Severe Community-acquired Pneumonia Due to Staphylococcus aureus, 2003–04 Influenza Season , 2006, Emerging infectious diseases.
[87] T. File. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[88] M. Bonten,et al. Impact of Rapid Detection of Viral and Atypical Bacterial Pathogens by Real-Time Polymerase Chain Reaction for Patients with Lower Respiratory Tract Infection , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] Tamara Pilishvili,et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. , 2005, JAMA.
[90] M. M. van der Eerden,et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study , 2005, Thorax.
[91] D. Talan,et al. Methicillin-resistant Staphylococcus aureus in Community-acquired Skin Infections , 2005, Emerging infectious diseases.
[92] Rangarajan Sampath,et al. Rapid identification and strain-typing of respiratory pathogens for epidemic surveillance , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[93] N. Sopena,et al. Multicenter study of hospital-acquired pneumonia in non-ICU patients. , 2005, Chest.
[94] Mian Cai,et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[95] J. Gerberding,et al. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. , 2005, MMWR. Morbidity and mortality weekly report.
[96] W. Thompson,et al. The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[97] D. Low,et al. Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 , 2003, Antimicrobial Agents and Chemotherapy.
[98] S. Cammarata,et al. Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies , 2003, Antimicrobial Agents and Chemotherapy.
[99] W. Lim,et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.
[100] A. Schuchat,et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. , 2003, The New England journal of medicine.
[101] Ronald N. Jones,et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. , 2002, Diagnostic microbiology and infectious disease.
[102] A. Kelly,et al. Venous pH can safely replace arterial pH in the initial evaluation of patients in the emergency department , 2001, Emergency medicine journal : EMJ.
[103] Inger,et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.
[104] I. Suramo,et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[105] M. Niederman,et al. The cost of treating community-acquired pneumonia. , 1998, Clinical therapeutics.
[106] G. Jackson. Infectious Diseases Society of America, Incorporated , 1971 .